CoChat

The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent

Open access
Purkins, Lynn, Wood, Nolan, Greenhalgh, Katie, Eve, Malcolm D., Oliver, Stuart D., Nichols, Don · 2003 · British Journal of Clinical Pharmacology
Cited by 116

The DOI matches its Crossref record.

Abstract

Aims Voriconazole is a new triazole with broad‐spectrum antifungal activity against clinically significant and emerging pathogens. These studies evaluated the pharmacokinetics and safety of intravenous voriconazole in healthy male volunteers. Methods Two single‐blind, placebo‐controlled studies were conducted. In Study A, 12 subjects were randomized to voriconazole (3 mg kg−1) or placebo, administered once daily on days 1 and 12, and every 12 h on days 3–11. In Study B, 18 subjects were randomized to voriconazole or placebo, with voriconazole being administered as a loading dose at 6 mg kg−1 twice on day 1, then at 3 mg kg−1 twice daily on days 2–9, and once at 3 mg kg−1 on day 10. Results In both studies, the plasma concentrations of voriconazole increased rapidly following the initiation of dosing. Minimum observed plasma concentration (Cmin) values at steady state were above the in vitro minimum inhibitory concentrations (MICs) for most fungal pathogens (Cmin > 0.8 µg ml−1). The use of a loading dose in Study B resulted in a shorter time to steady‐state Cmin values than was observed in Study A. Values of the final day plasma pharmacokinetic parameters in Studies A and B were similar: maximum observed plasma concentration (Cmax) 3621 and 3063 ng ml−1; areas under the plasma concentration–time curve from time zero to the end of the dosing interval (AUC τ) 16 535 and 13 245 ng·h ml−1, and terminal elimination phase half‐lives (t1/2) 6.5 and 6.7 h, respectively. On multiple dosing, voriconazole accumulated (AUC τ accumulation ratio 2.53–3.17, Study A) at a level that was not predictable from single‐dose data. The mean concentration–time profiles for voriconazole in saliva were similar to those in plasma. Multiple doses of voriconazole were well tolerated and no subject discontinued from either study. Seven cases of possibly drug‐related visual disturbance were reported in three subjects (Study B). Conclusions Administration of a loading dose of 6 mg kg−1 i.v. voriconazole on the first day of treatment followed by 3 mg kg−1 i.v. twice daily achieves steady state by the third day of dosing. This dosage regimen results in plasma levels of the drug that rapidly exceed the minimum inhibitory concentrations (MICs) against important fungal pathogens, including Aspergillus spp.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.2003.01992.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 116

Metadata

Authors
Purkins, L., Wood, N., Greenhalgh, K., Eve, M. D., Oliver, S. D., & Nichols, D.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2003-11-17
Volume
56
Issue
s1
Pages
2-9
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1558549775
Cited by
116
References
0
FWCI
2.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent. https://app.cochat.ai/papers/10.1046/j.1365-2125.2003.01992.x
The paper
Purkins, L., Wood, N., Greenhalgh, K., Eve, M. D., Oliver, S. D., & Nichols, D. (2003). The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2003.01992.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.